Download this PDF file
Crossref Citations
1. Leishmaniavaccines: progress and problems
L. KEDZIERSKI, Y. ZHU, E. HANDMAN
Parasitology vol: 133 issue: S2 first page: S87 year: 2006
doi: 10.1017/S0031182006001831
2. An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major
Eva Iniguez, Nathaniel S. Schocker, Krishanthi Subramaniam, Susana Portillo, Alba L. Montoya, Waleed S. Al-Salem, Caresse L. Torres, Felipe Rodriguez, Otacilio C. Moreira, Alvaro Acosta-Serrano, Katja Michael, Igor C. Almeida, Rosa A. Maldonado, Paulo Filemon Pimenta
PLOS Neglected Tropical Diseases vol: 11 issue: 10 first page: e0006039 year: 2017
doi: 10.1371/journal.pntd.0006039
3. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan
Roberta Olmo Pinheiro, Eduardo Fonseca Pinto, Herbert Leonel de Matos Guedes, Orlando Augusto Agrellos Filho, Katherine Antunes de Mattos, Elvira Maria Saraiva, Sergio Coutinho Furtado de Mendonça, Bartira Rossi-Bergmann
Vaccine vol: 25 issue: 14 first page: 2716 year: 2007
doi: 10.1016/j.vaccine.2006.05.093
4. Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates
Yari Cabezas, Laurent Legentil, Florence Robert-Gangneux, Franck Daligault, Sorya Belaz, Caroline Nugier-Chauvin, Sylvain Tranchimand, Charles Tellier, Jean-Pierre Gangneux, Vincent Ferrières
Organic & Biomolecular Chemistry vol: 13 issue: 31 first page: 8393 year: 2015
doi: 10.1039/C5OB00563A
5. Identifying vaccine targets for anti-leishmanial vaccine development
Shyam Sundar, Bhawana Singh
Expert Review of Vaccines vol: 13 issue: 4 first page: 489 year: 2014
doi: 10.1586/14760584.2014.894467
6. Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate?
Claire-Lise Forestier, Qi Gao, Geert-Jan Boons
Frontiers in Cellular and Infection Microbiology vol: 4 year: 2015
doi: 10.3389/fcimb.2014.00193
